Nuclear transcription factor-kappaB as a target for cancer drug development.
Nuclear factor kappa B (NF-kappaB) is a family of inducible transcription factors found virtually ubiquitously in all cells. Since its discovery by Sen and Baltimore in 1986, much has been discovered about its mechanisms of activation, its target genes, and its function in a variety of human diseases including those related to inflammation, asthma, atherosclerosis, AIDS, septic shock, arthritis, and cancer. Due to its role in a wide variety of diseases, NF-kappaB has become one of the major targets for drug development. Here, we review our current knowledge of NF-kappaB, the possible mechanisms of its activation, its potential role in cancer, and various strategies being employed to target the NF-kappaB signaling pathway for cancer drug development.
Garg
A
A
Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aggarwal
B B
BB
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D017353:Gene Deletion; D006801:Humans; D008954:Models, Biological; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000628:therapy
D000970:Antineoplastic Agents; D016328:NF-kappa B